Tempest Therapeutics, Inc. TPST
Nov 4, 2026, 3:33 PM EST
- YTD
- -84.08%
- 1 year
- -94.99%
- Market cap
- 9.14M
- EPS (ttm)
- -3.93
- Shares out
- 43.64M
- Forward P/E
- -0.61
- YTD return
- -84.08%
- 1-year return
- -94.99%
- Volume
- 92.10K
- Avg volume
- 2.58M
- Open
- 0.4701
- Previous close
- 0.4686
- Day's range
- 0.4552 – 0.4997
- 52-week range
- 0.4552 – 10.33
- Beta
- -2.78
- Analysts
- Buy
- Price target
- 18.75 (+4002.8%)
5D -0.0139 (-2.72%)
Key statistics
- Enterprise value
- 13.50M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.70
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -15.20M
- Total cash
- 31.12M
- Total debt
- 20.25M
- Return on equity
- -289.26%
- Short % of float
- 12.62%
- 50-day average
- 0.95482
- 200-day average
- 2.12
Analyst view
Consensus: buy
- Target (low)
- 5.00
- Target (mean)
- 18.75
- Target (high)
- 47.00
- Strong buy3
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.245.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.37 | -0.41 | -0.04 | -10.81% |
| Aug 8, 2024 | Jun 1, 2024 | -0.47 | -0.42 | +0.05 | +10.64% |
| May 9, 2024 | Mar 1, 2024 | -0.44 | -0.36 | +0.08 | +18.18% |
| Mar 19, 2024 | Dec 1, 2023 | -0.38 | -0.34 | +0.04 | +10.53% |
| Nov 8, 2023 | Sep 1, 2023 | -0.55 | -0.48 | +0.07 | +12.73% |
| Aug 10, 2023 | Jun 1, 2023 | -0.58 | -0.54 | +0.04 | +6.90% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 13, 2024 | Piper Sandler | main | Overweight | Overweight |
| Nov 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 10, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 21, 2024 | Piper Sandler | reit | Overweight | Overweight |
| Jun 20, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Tempest Therapeutics, Inc.
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. The company has agreement with Roche to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq®) and bevacizumab. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tempesttx.com
News
12 Health Care Stocks Moving In Friday's Pre-Market Session - 12 Health Care Stocks Moving In Wednesday's After-Market Session
Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise 
12 Health Care Stocks Moving In Monday's After-Market Session 
Tempest signs related-party R&D pact, reshapes leadership 
Tempest Therapeutics Files Prospectus Registering Resale Of Up To 9,534,164 Shares Of Common Stock 
HC Wainwright & Co. Maintains Buy on Tempest Therapeutics, Lowers Price Target to $7 
Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors - 12 Health Care Stocks Moving In Monday's Intraday Session
- 12 Health Care Stocks Moving In Thursday's Intraday Session
Your note
Sign in to keep a note on TPST — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRADY STEPHEN R | Chief Executive Officer | Purchase | Jul 2, 2024 | 46,376 |
| TROJANOWSKI JUSTIN | Officer | Purchase | Jun 27, 2024 | 22,168 |
| VERSANT VENTURE CAPITAL VI, L.P. | Beneficial Owner of more than 10% of a Class of Security | Sale | Aug 11, 2024 | 3,507,060 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 1.26% | 551,587 | 466.97K | Sep 29, 2024 |
| Altium Capital Management, LP | 1.25% | 545,000 | 461.40K | Sep 29, 2024 |
| FMR, LLC | 0.99% | 431,932 | 365.67K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.50% | 220,067 | 186.31K | Sep 29, 2024 |
| Vanguard Group Inc | 0.40% | 176,193 | 149.16K | Sep 29, 2024 |
| FIL LTD | 0.30% | 129,579 | 109.70K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.40% | 174,007 | 147.31K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.28% | 122,163 | 103.42K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.10% | 43,373 | 36.72K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.09% | 39,717 | 33.62K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.07% | 29,135 | 24.66K | Oct 30, 2024 |
| DFA U.S. Small Cap Series | 0.05% | 23,577 | 19.96K | Jul 30, 2024 |